Stage (next event)
Phase 3 (Safety and Efficacy Data)
Catalyst Info & Data Links
TITLE: Tradipitant for COVID-19 - Phase 3 Safety & Efficacy Data
ClinicalTrial.gov (NCT04326426): ODYSSEY: A Study to Investigate the Efficacy of Tradipitant in Treating Severe or Critical COVID-19 Infection
WHAT IS THE NEXT CATALYST EVENT?
WHEN WILL THE EVENT (OR DID THE EVENT) OCCUR?
2019: Tradipitant complete responder analysis in gastroparesis patients: 1238. American Journal of Gastroenterology, 114(2019 ACG Annual Meeting Abstracts), S691.
2020: Tradipitant Treatment Caused Clinically Meaningful and Significant Improvement in Nausea and Other Symptoms of Gastroparesis in a Phase II Study. Gastroenterology, 158(6), S-189.
Mechanism of Action
MECHANSIM OF ACTION / RATIONALE
Tradipitant is an orally bioavailable, centrally-acting, selective, neurokinin 1 receptor (NK1-receptor; NK1R; NK-1R) antagonist with potential anti-emetic, anti-pruritic and anti-inflammatory activities. Upon oral administration, tradipitant competitively binds to and blocks the activity of the NK1R in the central nervous system (CNS), thereby inhibiting the binding of the endogenous ligand and neuropeptide, substance P (SP; neurokinin-1; NK1). This inhibits SP/NK1-mediated signal transduction and may prevent both SP-induced emesis and pruritis. In addition, inhibition of SP/NK1R signaling also reduces neurogenic inflammation which is triggered by the release of neuropeptides, such as substance P, from nerve cells. NK1R is a G protein-coupled receptor (GPCR) that preferentially binds to SP, a neuropeptide secreted by neuronal cells and inflammatory cells. (source - National Library of Medicine (National Institute of Health))
Updated by HC
Prior Data (click to view full image)
Trial Design / Revenue (click to view full image)
See what the community is saying - click to see full post